Leading developer of personal care products DS Healthcare Group announced it has appointed Aptiv Solutions as its clinical research organization (CRO) for a proprietary topical prescription treatment. The drug, if approved, will be positioned as a frontline therapy against hair loss.

DS Healthcare’s Investigational New Drug Application (IND) for this proprietary topical hair loss treatment will be prepared by Aptiv Solutions for submission to the FDA. Only one other topical hair loss treatment has been approved by the FDA to date. Additionally, Aptiv Solutions will conduct a Gap analysis to ensure that DS Healthcare’s operations are in line with regulatory requirements for drug approval.

A leading global CRO with extensive global drug development and trial management expertise, Aptiv Solutions has conducted more than 2,600 clinical trials and has assisted with more than 140 FDA and European Union drug and biologic approvals and more than 700 medical device approvals and clearances.

Recently, DS Healthcare announced its intention to submit an IND to the FDA – a move that follows the company’s patent application filing with the U.S. Patent and Trademark Office for its invention of the prescription hair loss treatment.

For more information, visit www.dslaboratories.com

Let us hear your thoughts below: